Pharmacology 2 3 2016__.Pdf

RESEARCH RESULT: PHARMACOLOGY AND CLINICAL PHARMACOLOGY Рус. Eng. The journal has been registered at the Federal service for supervision of communications information technology and mass media (Roskomnadzor) Mass media registration certificate El. № FS 77-55674 of October 28, 2013 Volume 2, № 3. 2016 ONLINE SCHOLARLY PEER-REVIEWED JOURNAL First published online: 2014 ISSN 2500-235X EDITORIAL TEAM: EDITOR-IN-CHIEF: Mikhail V. Pokrovskii, Academician of the Russian Academy of Natural, Doctor of Medical Sciences, Professor, Head of the Department of Pharmacology, Institute of Medicine, Belgorod State National Research University. DEPUTY EDITOR-IN-CHIEF: Pavel A. Galenko-Yaroshevsky, Corresponding member of Russian Academy of Sciences, Doctor of Medical Sciences, Professor, Kuban State Medical University, Russia. EXECUTIVE SECRETARY: Oleg S. Gudyrev, Ph.D. of Medical Sciences, Associate Professor, Department of Pharmacology, Institute of Medicine, Belgorod State National Research University. ENGLISH TEXT EDITOR: Igor Lyashenko, Ph.D. in philology, Associate Professor, Department of English Philology and Intercultural Communication, Institute of Intercultural Communication and International Relations, Belgorod State National Research University. EDITORIAL BOARD: Tatyana G. Pokrovskaya, Doctor of Medical Sciences, Professor of the Department of Pharmacology, Institute of Medicine, Belgorod State National Research University. Mikhail V. Korokin, Doctor of Medical Sciences, Professor of the Department of Pharmacology, Institute of Medicine, Belgorod State National Research University. CONSULTING EDITORS: Elena B. Artyushkova, Doctor of Biology Sciences, Professor, Director of the Research Institute of Environmental Medicine, Kursk State Medical University, Russia. Tatyana V. Avtina, Ph.D in Pharmaceutical Sciences, Associate Professor, Department of Pharmacology, Institute of Medicine, Belgorod State National Research University. Natalia D. Bunyatyan, Doctor of Pharmacy Sciences, Professor, Deputy Director General for Research Federal State Budgetary Institution «Scientific Center for Expertise of Medical Application Products» of the Ministry of Health of the Russian Federation, Russia. Dr. Klaus Witte, Managing Director Abbot Laboratories GmbH, Germany Evgeny A. Konorev, Doctor of Medical Sciences, Professor, University of Kansas City, USA. Konstantin M. Reznikov, Doctor of Medical Sciences, Professor of the Department of Pharmacology, Voronezh State Medical University Named after N.N. Burdenko, Russia. Tatyana A. Savitskaya, PhD in Chemistry, Professor of the Department of Physical Chemistry, Belarusian State University, Belorussia. Lev N. Sernov, Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, General Director of "Farmkonsalting", Russia. Dmitry E. Skopin, Doctor of Physico-Mathematical Sciences, Professor, University "Al Balqa Applied", Jordan. Sergei Y. Shtrygol, Doctor of Medical Sciences, Professor, National University of Pharmacy, Ukraine. Founder: Federal state autonomous educational establishment of higher professional education «Belgorod State National Research University» Publisher: Belgorod State National Research University Address of publisher: 85 Pobeda St., Belgorod, 308015, Russia Publication frequency: 4 /year © Belgorod State National Research University, 2016 CONTENTS EXPERIMENTAL PHARMACOLOGY Bogus S.K., Kulikov A.L., Vinakov D.V., Suzdalev K.P., Galenko-Yaroshevskii P.A. Anticholinergic activity and pharmacokinetic parameters of agent SS-68 with properties of class III antiarrhythmic drugs 3 Gureev V.V. New approaches of morfofunktional pharmacological correction of violations of cardiovascular system in experimental preeclampsia 11 Yakushev V.I., Pokrovskii M.V. Cardiovascular effects of an arginase II selective inhibitor 28 CLINICAL PHARMACOLOGY Chuhareva N.A., Bontsevich R.A., Shchurovskaya K.V., Denisova D.S. The choice of antimicrobial therapy among physicians in the treatment of gestational pyelonephritis 46 Kornilov A. A., Luneva J. V., Povetkin S.V. Comprehensive evaluation of combined pharmacotherapy of cardiac pathology considering exogenous and pharmacogenetic factors 51 Kukes V.G. , Gorbach T.V. , Romashchenko O.V. , Rumbesht V.V. АT P as the marker of power exchange condition at the experimental ischemia of the myocardium due to metabolic drugs introduction 58 VETERINARY PHARMACOLOGY Bui Quang Cu , Nguen Hoai Chao, Vesentsev A.I., Buhanov V.D. , Sokolovsky P.V., Mihaylyukova M.O. The antibacterial properties of modified bentonite deposit tam bo 63 Zuev N.P., Bukhanov V.D., Vezentsev A.I., Sokolovskiy P.V., Khmirov A.V., Zueva E.N., Salashnaya E.А., Mihaylyukova M.O. The etiological structure of mass diseases with young gastro and respiratory syndrome 75 PHARMACOLOGYCAL REVIEWS Avdeeva N.V., Nikitina V.A., Kochkarova I.S., Litvinova A.S. The possibility of administration of glutamate receptors antagonists in the treatment of parkinson's disease 86 Danilenko L.M., Klochkova G.N., Kizilova I.V., Korokin M.V. Pharmacological preconditioning by recombinant erythropoietin as the possibility of increasing the stability of tissue of the retina to reperfusion ischemia in experiment 95 Martynov M.A., Martynova O.V., Shkileva I.Y., Tokarev I.A., Dovgan A.N. Thymosin β4 as basis for creation of a reparation preparation of new generation 101 Reznikov K.M. Paradigm of modern pharmacology: development and current approaches 107 Bogus S.K., Kulikov A.L., Vinakov D.V., Suzdalev K.P., Galenko-Yaroshevskii P.A. Anticholinergic activity and pharmacokinetic parameters of agent SS-68 with properties of class III antiarrhythmic 3 drugs. Research result: pharmacology and clinical pharmacology. Vol. 2, №3 (2016): 3-10. Рус. Eng. EXPERIMENTAL PHARMACOLOGY UDC: 616.12-008.313:615.222:615.015]-092.9 DOI: 10.18413/2500-235X-2016-2-3-3-10 Bogus S.K.1 Kulikov A.L.2 ANTICHOLINERGIC ACTIVITY AND PHARMACOKINETIC Vinakov D.V.3 PARAMETERS OF AGENT SS-68 WITH PROPERTIES OF CLASS III Suzdalev K.P.4 ANTIARRHYTHMIC DRUGS Galenko-Yaroshevskii P.A.5 1) PhD of Medical Sciences, Assistant of the Department of Pharmacology of Kuban State Medical University. 4, Sedina st., Krasnodar, 350063, Russia, e-mail: [email protected] 2) Postgraduate student of the Department of Pharmacology of Medical institute of Belgorod State University 85, Pobedy St., Belgorod, 308015, Russia, e-mail: [email protected] 3) Postgraduate student of the Department of Pharmacology of Medical institute of Belgorod State University 85, Pobedy St., Belgorod, 308015, Russia, e-mail:[email protected] 4) PhD of Chemical Sciences, assistant professor of the Department of chemistry of natural and macromolecular compounds, Southern Federal University, 7, Zorge st., Rostov-on-Don, 344090, Russia, e-mail:[email protected] 5) Corresponding member of Russian Academy of Sciences, Doctor of Medicine, Prof. of of Kuban State Medical University 4, Sedina st., Krasnodar, 350063, Russia, e-mail: [email protected] Abstract It was shown that the indole derivate SS-68 (50 and 250 µg/kg intravenous) in acute experiments on cats with neurogenic atrial fibrillation (AF) has a dose-dependent antiarrhythmic action which is associated with the neurotropic influence of this substance, since the suppression of the AF coincides with its anticholinergic effect observed for more than 2 hours, but cardiotropic action at this time was not observed. High antiarrhythmic activity of SS-68 to neurogenic AF may be due to the IKAch inhibition and blockade of M2-cholinergic receptors. SS-68 (50 µg/kg intravenous) in experiments on rabbits is characterized by the following pharmacokinetic parameters: Cmax = 14.5 ng/ml of blood plasma (duration of plasma exposure of SS-68 is 4 hours), T1/2 = 1,1 ± 0.06 hours, MRT(0 – t) = 1.6 ± 0.08 hours, AUC(0 – 1440) = 1006.1 ± 147.7 ng/ml×min, Vss = 4.8 ± 0.8 l/kg and CL = 0.051 l/h. Based on pharmacodynamic and pharmacokinetic parameters it was suggested that anticholinergic action of SS-68 in neurogenic AF will occur in a much lower dose than 50 mg/kg. Key words: vagus nerve, neurogenic atrial fibrillation, indole derivate SS-68, antiarrhythmic action, pharmacokinetics. Introduction reason enough to call this arrhythmia "global Atrial fibrillation is the most common heart beat epidemic" [3, 4, 5]. disorder. For the 50-year period of observation in the In recent years in the treatment of AF there is Framingham study, the morbidity of AF corrected to the preference for class III antiarrhythmic drugs age increased fourfold [1]. From 1990 to 2010, the (classification by E. M. Vaughan-Williams [6]), prevalence of AF in the world and associated with it acting mainly at the expense of slowing morbidity and mortality, despite all efforts of medical repolarization and increasing the duration of science and health care increased twofold [2]. refractory periods [7]. According to forecasts over the next 3 decades the Despite the fact that to the present time in our number of patients with AF in Europe and the United country and abroad there were created a number of States will increase by more than twofold, which is different on the effectiveness and mechanism of RESEARCH RESULT: PHARMACOLOGY AND CLINICAL PHARMACOLOGY Bogus S.K., Kulikov A.L., Vinakov D.V., Suzdalev K.P., Galenko-Yaroshevskii P.A. Anticholinergic activity and pharmacokinetic parameters of agent SS-68 with properties of class III antiarrhythmic 4 drugs. Research result: pharmacology and clinical pharmacology. Vol. 2, №3 (2016): 3-10. action of class III antiarrhythmic

Load more